Section Arrow
Quote
NEUP.NASDAQ
- Neuphoria Therapeutics Inc
Quotes are at least 15-min delayed:2026/11/04 14:46 EST
Regular Hours
Last
 3
+0.01 (+0.33%)
Day High 
3.07 
Prev. Close
2.99 
1-M High
3.5899 
Volume 
49.16K 
Bid
3
Ask
3.07
Day Low
2.98 
Open
3.05 
1-M Low
2.99 
Market Cap 
16.18M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.27 
20-SMA 3.3 
50-SMA 3.54 
52-W High 5.53 
52-W Low 2.99 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.06/-3.52
Enterprise Value
16.18M
Balance Sheet
Book Value Per Share
4.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.17M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.2101+0.4962+69.51%0.2PE
KPTIKaryopharm Therapeutics Inc.0.0862-0.0021-2.38%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.6497-0.0103-0.62%-- 
NRIXNurix Therapeutics16.29-9.53-36.91%10.63PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator ofthe alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.